SML2269
LY404039
≥98% (HPLC)
别名:
(1R,4S,5S,6S)-4-Amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid 2,2-dioxide, (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid, LY 404039, LY-404,039, LY-404039
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C7H9NO6S
化学文摘社编号:
分子量:
235.21
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI
1S/C7H9NO6S/c8-7(6(11)12)1-15(13,14)4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1
SMILES string
[H][C@]1([C@@](C(O)=O)(N)C2)[C@@]([C@@H]1C(O)=O)([H])S2(=O)=O
InChI key
AVDUGNCTZRCAHH-MDASVERJSA-N
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -69 to -79°, c = 1.0 in 1 M NaOH
color
white to gray
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
−20°C
Biochem/physiol Actions
LY404039 is a potent and selective group II metabotropic glutamate receptors mGluR2/3 agonist (Ki = 15 nM against against [3H]LY341495 for binding rat neurons; Ki = 149 nM and 92 nM, respectively, using membrane from human mGluR2- or mGluR3-expressing cells) with >100-fold selectivity over 16 other receptors/transproters, including iGluRs and EAAT1/2/3. LY404039 inhibits forskolin-stimulated c-AMP production in RGT cells expressing human mGluR2 (EC50 = 23 nM) or mGluR3 (EC50 = 48 nM) with little or no potency toward mGluR1a/5a/4a/6/7a/8a-expressing cells (EC50 >10 μM). LY404039 is orally available (Cmax 1528.5 ng/mL, Tmax 2 h; 10 mg/kg p.o. in rats) and exhibits antipsychotic and anxiolytic efficacy in rats (3-30 mg/kg) in vivo.
Orally available, potent and selective metabotropic glutamate receptors mGluR2 & mGluR3 agonist with antipsychotic and anxiolytic efficacy in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
James A Monn et al.
Journal of medicinal chemistry, 50(2), 233-240 (2007-01-19)
(-)-4-Amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate (LY389795, (-)-3) is a highly potent and selective agonist of metabotropic glutamate receptors 2 (mGlu2) and 3 (mGlu3). As part of our ongoing research program, we have prepared S-oxidized variants of (-)-3, compounds (-)-10, (+)-11 (LY404040), and (-)-12 (LY404039).
Cameron S Metcalf et al.
Epilepsia, 58(3), 484-493 (2017-02-07)
The metabotropic glutamate receptor subtype 2 (mGlu2 ) possesses both orthosteric and allosteric modulatory sites, are expressed in the frontal cortex and limbic structures, and can affect excitatory synaptic transmission. Therefore, mGlu2 is a potential therapeutic target in the treatment
Zachary A Rodd et al.
Behavioural brain research, 171(2), 207-215 (2006-05-09)
Metabotropic glutamate (mGlu) receptors have been shown to mediate a number of behaviors including emotionality and responsivity to stress as demonstrated by efficacy in preclinical and clinical studies. The objective of this study was to assess the effects of the
Linda M Rorick-Kehn et al.
The Journal of pharmacology and experimental therapeutics, 321(1), 308-317 (2007-01-06)
Group II metabotropic glutamate (mGlu) receptor agonists, including (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), have demonstrated efficacy in animal models of anxiety and schizophrenia, and LY354740 decreased anxiety in human subjects. Herein, we report the in vitro pharmacological profile and
Linda M Rorick-Kehn et al.
Psychopharmacology, 193(1), 121-136 (2007-03-27)
Data from both preclinical and clinical studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor agonists, might provide therapeutic benefits in many psychiatric disorders including schizophrenia and anxiety. The aim of this study
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持